Interested in Zai Lab Limited Unsponsored ADR? Here are five stocks we like better.
Q2 net product revenue rose 11% sequentially to $105.8 million, supported by VYVGART volume growth, steady ZEJULA sales, XACDURO strength and the early KarXT launch. Management expects revenue to stabilize in late 2026 before returning to meaningful year-over-year growth in 2027, with $717.5 million in cash at quarter-end.
Zoci development is expanding toward potential U.S. approval. Zai Lab expects three registrational programs by the end of 2026, plans to complete a Phase III small-cell lung cancer enrollment in the first half of 2027 and anticipates a possible accelerated-approval filing later that year, with potential approval in 2028.
The company continues advancing its global pipeline, including ZL-1503 for atopic dermatitis, ZL-6201 for solid tumors and ZL-1311 for gastrointestinal cancers. Zai Lab also expects its first U.S. regulatory submission next year as it transitions from a China-focused business into a global biopharmaceutical company.
Zai Lab Stock Has Fallen to Value Levels
#expects #Potential #global
Q2 net product revenue rose 11% sequentially to $105.8 million, supported by VYVGART volume growth, steady ZEJULA sales, XACDURO strength and the early KarXT launch. Management expects revenue to stabilize in late 2026 before returning to meaningful year-over-year growth in 2027, with $717.5 million in cash at quarter-end.
Zoci development is expanding toward potential U.S. approval. Zai Lab expects three registrational programs by the end of 2026, plans to complete a Phase III small-cell lung cancer enrollment in the first half of 2027 and anticipates a possible accelerated-approval filing later that year, with potential approval in 2028.
The company continues advancing its global pipeline, including ZL-1503 for atopic dermatitis, ZL-6201 for solid tumors and ZL-1311 for gastrointestinal cancers. Zai Lab also expects its first U.S. regulatory submission next year as it transitions from a China-focused business into a global biopharmaceutical company.
Zai Lab Stock Has Fallen to Value Levels
#expects #Potential #global
2 months ago
